{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:24:57Z","timestamp":1743654297953,"version":"3.40.3"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bulcan.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:23:45Z","timestamp":1741177425000},"page":"364-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["L\u2019odronextamab dans les lymphomes B diffus \u00e0 grandes cellules et lymphomes folliculaires en rechute ou r\u00e9fractaire en troisi\u00e8me ligne"],"prefix":"10.1016","volume":"112","author":[{"given":"Arthur","family":"Coste","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2025.01.011_bib0030","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.bulcan.2023.06.010","article-title":"Cellules CAR-T lisocabtagene maraleucel en deuxi\u00e8me ligne dans le lymphome non hodgkinien B agressif en rechute pr\u00e9coce ou r\u00e9fractaire","volume":"110","author":"Chanut","year":"2023","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2025.01.011_bib0035","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3\u00a0bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1\u00a0trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2025.01.011_bib0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2\u00a0ELM-2\u00a0study: Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2025.01.011_bib0045","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2025.01.011_bib0025","doi-asserted-by":"crossref","first-page":"TPS7096","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096","article-title":"Phase 3\u00a0trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1)","volume":"42","author":"Birhiray","year":"2024","journal-title":"JCO"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:21:50Z","timestamp":1743639710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0007455125000736"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.01.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019odronextamab dans les lymphomes B diffus \u00e0 grandes cellules et lymphomes folliculaires en rechute ou r\u00e9fractaire en troisi\u00e8me ligne","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}